A Phase 2 interventional study of TQH2722 injection and TQH2722 Placebo in Seasonal Allergic Rhinitis, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Completed at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 13th largest by enrollment, is one of 9 that started in 2025, is one of 12 in phase 2, and was the 12th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
Chengdu Kangnuoxing Biopharma,Inc. · Sites in China
Ages 12–18
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18–75
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Shanghai Mabgeek Biotech.Co.Ltd · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 11
First in 2017; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 160 across the 27 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.
Sino Biopharmaceutical Limited has 3 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
5 of the studies in Rhinitis, Allergic, Seasonal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07688772Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07678931Phase 3Chengdu Kangnuoxing Biopharma,Inc.Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07199257Phase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | 2027-05-15 |
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07398859Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | 2026-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TQH2722 injection
TQH2722 placebo, 1 weeks as a treatment cycle.
Drug: TQH2722 Placebo
TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
Placebo without drug substance.
Retrospective nasal symptom score after treatment for 2 weeks
Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 2 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 weeks
Retrospective nasal symptom score after treatment for 4 weeks
Mean daily retrospective nasal symptom total score (rTNSS) changes from baseline at 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 4 weeks
Mean daily changes in retrospective nasal symptom total score
Mean daily changes in retrospective nasal symptom total score (AM rTNSS) from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Mean daily nightly retrospective nasal symptom total score
Mean daily nightly retrospective nasal symptom total score (PM rTNSS) changes from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean change of instantaneous nasal symptom total score (iTNSS) from baseline
Mean change of instantaneous nasal symptom total score (iTNSS) from baseline every morning before treatment for 2 weeks and 4 weeks. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean daily rTNSS change from baseline
Mean daily rTNSSchange from baseline at 2 weeks and 4 weeks of treatment; The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal symptom score: Mean change rate of iTNSS from baseline
Mean change rate of iTNSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in daily retrospective nasal symptom scores
Mean changes from baseline in daily retrospective nasal symptom scores (runny nose, nasal congestion, nasal itchy, and sneezing) at 2 and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms during the day
Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, itchy nose, and sneezing) were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms at night
Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, nasal itchy and sneezing) at night (PM) after 2 and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean changes in daily retrospective ocular symptom score
Mean changes in daily retrospective ocular symptom score (rTOSS) from baseline at 2 and 4 weeks of treatment; The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean changes in retrospective ocular symptom score during the day
Mean daily changes in retrospective ocular symptom score (AM rTOSS) from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean retrospective ocular symptom score at night
Mean nightly retrospective ocular symptom score (PM rTOSS) changes from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean change of instantaneous ocular symptom total score
Mean change of instantaneous ocular symptom total score (iTOSS) from baseline every morning at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Retrospective ocular symptom score: Mean rate of change in daily rTOSS
Mean rate of change in daily rTOSS from baseline at 2 and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Retrospective nasal symptom score: Average daily retrospective nasal symptom score
Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 4 weeks of treatment. The total score is 0-12points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 4 weeks
Retrospective ocular symptom score: Mean change rate of iTOSS each morning
Mean change rate of iTOSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-9 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes in scores of individual ocular symptoms
Average changes in scores of individual ocular symptoms (itchy, tearing, red eyes) at 2 and 4 weeks of treatment compared with baseline. The single score is 0-3 points, with the higher score meaning the more severe symptoms
Time frame: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes of individual ocular symptom scores during the day
Average changes of individual ocular symptom scores (itchy, watery eyes, red eyes) compared with baseline were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Instantaneous ocular single symptom score: Average changes of individual ocular symptoms at night
Average changes of individual ocular symptoms (itchy, watery eyes, red eyes) scores at night (PM) after 2 weeks of treatment and 4 weeks of treatment compared with baseline. The single score is 0-3 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Quality of life questionnaire
Changes in quality of life questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment. The total score is 0-168 points, with the higher score meaning the more severe symptoms.
Time frame: Baseline up to 2 and 4 weeks
Time of onset
Time of onset after treatment.
Time frame: Baseline up to 4 weeks
Time to Reach Maximum Plasma Concentration (Tmax)
Time to reach maximum plasma concentration after administration.
Time frame: Baseline up to 4 weeks
Area under the curve
Area under the curve of mean daily rTNSS change from baseline at 2 and 4 weeks of treatment
Time frame: Baseline up to 2 and 4 weeks
Number of days with no or mild symptoms of Allergic rhinitis symptoms
Number of days with no or mild symptoms during 2 weeks and 4 weeks of treatment
Time frame: Baseline up to 2 and 4 weeks
Adverse event rate
Incidence and severity of adverse events (AE) and serious adverse events (SAE), physical examination, vital signs, 12-lead electrocardiogram (ECG), and abnormal laboratory indicators.
Time frame: Baseline up to 12 weeks
Ran from Mar 2025 to primary completion in Apr 2025, 1 month.
Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQH2722
Rhinitis, Allergic, Seasonal →
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. →